BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
BioStem Technologies (OTC: BSEM) announces its participation in the 24th Annual Needham Virtual Healthcare Conference, where CEO Jason Matuszewski will present on April 10, 2025, at 1:30 PM ET. The company will also conduct investor meetings during the conference.
BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using their proprietary BioREtain® processing method. Their product portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®.
The company maintains AATB accreditation and operates an FDA-registered facility in Pompano Beach, Florida, following Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP). Their processing method focuses on maintaining growth factors and preserving tissue structure for optimal wound care solutions.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BSEM declined 3.24%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The presentation will be webcast at 1:30 PM ET on April 10, 2025
POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason Matuszewski, will present at the 24th Annual Needham Virtual Healthcare Conference at 1:30 PM ET on Thursday, April 10, 2025. Management will also be hosting investor meetings during the conference.
BioStem Technologies Presentation Access:
- Presenter: Jason Matuszewski, Chief Executive Officer
- Date: Thursday, April 10, 2025
- Time: 1:30 PM ET
- Webcast Link & Archive: HERE
- 1-on-1 Meeting Request: Conferences@needhamco.com
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain®processing method. BioREtain®has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on X and LinkedIn.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Investor Relations
Adam Holdsworth
adamh@pcgadvisory.com
917-497-9287
FAQ
When and where will BioStem Technologies (BSEM) present at the Needham Healthcare Conference?
What products are in BioStem Technologies' (BSEM) current portfolio?
What is BioStem Technologies' (BSEM) BioREtain® processing method?
What certifications does BioStem Technologies' (BSEM) manufacturing facility have?
How can investors participate in BioStem Technologies' (BSEM) Needham Conference presentation?
